Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 2011. The report details a specific share repurchase transaction executed on March 29, 2011, under authority granted by shareholders at the Annual General Meeting on May 6, 2010.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 225,000 Ordinary shares of 25 pence each.
- Price Range: Highest price paid was 1,184.5 pence per share; lowest price paid was 1,175.5 pence per share.
- Treasury Holdings: The Company holds 493,224,284 shares in Treasury.
- Treasury Percentage: Represents 8.71% of total issued share capital and 9.54% of total voting rights.
- Shares in Issue: 5,171,700,752 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of outstanding share capital through the purchase and subsequent cancellation of 225,000 shares. The filing does not provide comparative data against prior periods for financial performance.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies. It is a compliance disclosure confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules and explicitly states it does not constitute an offer to purchase securities.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (493,224,284) against the latest annual report.
- Confirm the calculation of voting rights (9.54%) based on the total issued share capital.
- Check subsequent filings for further share repurchase activity under the May 2010 shareholder authority.
- Note that this document does not contain operational or financial performance data for the quarter.